| |||
| |||
| |||
Clive Maund, CliveMaund.com(12/28/20) |
|||
|
|||
| |||
| |||
| |||
![]() |
André Uddin, Mackie Research Capital(12/15/20) |
||
|
|||
Clive Maund, CliveMaund.com(12/8/20) |
|||
|
|||
| |||
| |||
| |||
| |||
| |||
| |||
| |||
| |||
| |||
All Penny Stocks(8/24/20) |
|||
|
|||
![]() |
André Uddin, Mackie Research Capital(8/19/20) |
||
|
|||
| |||
Baystreet(8/12/20) |
|||
|
|||
|
Knox Henderson | |
Clive Maund – CliveMaund.com | |
![]() |
André Uddin – Mackie Research Capital |
The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.See disclaimer for more details.
Algernon Pharmaceuticals Inc. (OTC: AGNPF) (CSE: AGN) is one of the few companies still flying under the radar of the masses, potentially giving one of the last “ground floor” looks at a coronavirus stock before a pending breakout | |
Algernon Pharmaceuticals Inc. (OTC: AGNPF) (CSE: AGN) already has a proven drug that has a strong safety history and was developed by one of the top names in biotech, Sanofi. | |
Algernon Pharmaceuticals Inc. (OTC: AGNPF) (CSE: AGN) has already received positive Feedback from U.S. FDA for Ifenprodil COVID-19 Human Trial and is now approved for a Phase 2 clinical study in South Koreau cleared for a Phase 2b/3 human trial in CA |
![]() Q2 2020 |
US FDA IND submission Phase 2b/3 May 15th, 2020
|
![]() Q2 2020 |
First patient in Phase 2 study in South Korea – May 15th , 2020
|
![]() Q2 2020 |
Ethics and regulatory approval for Phase 2 idiopathic pulmonary fibrosis (IPF) & chronic cough study
|